2019

04/24/2019 Guerbet receives CE mark approval for SeQure® and DraKon™ microcatheters for interventional imaging

Villepinte, France, April 24th, 2019 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, announces the upcoming European launch of SeQure® and DraKon™, two novel microcatheters for peripheral embolization procedures. SeQure® and DraKon™...

[more]


04/18/2019 1st quarter 2019 revenue

1st quarter 2019 revenue Year off to a good start: • €197.3 million; +7.7% at current exchange rates• €195.4 million; +6.7% at constant exchange rates Villepinte, 18 April 2019 - Guerbet (FR0000032526 GBT), a global specialist in contrast agents and solutions for medical imaging, is...

[more]


04/10/2019 Guerbet teams will attend IFFS 2019!

The 2019 edition of the IFFS congress (International Federation of Fertility Societies) will be held in Shanghai, China from April 11th to 14th. IFFS stimulates basic and clinical research, disseminates education, and encourages superior clinical care of patients in infertility and...

[more]


03/26/2019 2018 annual results

Growth and EBITDA in line with announced targets › Reported revenue: €789.6 million › Revenue at constant exchange rates: €825.7 million; +2.3%, in line with the guidance given at Capital Markets Day in April 2018 (GEAR 2023 plan) › Reported EBITDA: €110.6 million, also in line with the...

[more]


02/14/2019 2018 revenue

Activity growth consistent with the objectives:  +2.3% at constant exchange rates, or €825.7 million Villepinte, 14 February 2019 – Guerbet (FR0000032526), a global specialist in contrast agents and solutions for medical imaging, is reporting revenue of €789.6 million at 31 December...

[more]


01/24/2019 Guerbet enriches the visitor experience at Tech Gate during ECR 2019, Vienna

Villepinte (France), January 24, 2019 – Guerbet, the global specialist in contrast media and solutions for diagnostic and interventional imaging, invites delegates to the upcoming ECR 2019 meeting to a totally innovative method of becoming acquainted with the company’s new strategies and products....

[more]